Results 181 to 190 of about 1,470 (198)

Efgartigimod alfa (Vyvgart) for myasthenia gravis.

The Medical letter on drugs and therapeutics, 2022
openaire   +1 more source

Efgartigimod-alfa/mycophenolate/pyridostigmine

Reactions Weekly
openaire   +1 more source

Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: A single-center case series

Journal of Neuroimmunology
Ye Hong, Shen Liu
exaly  

Perioperative Safety and Efficacy of Efgartigimod for Thymoma-Associated Myasthenia Gravis: A Prospective, Multicenter, Phase II Clinical Trial

Journal of Thoracic Oncology
Sushan Luo, Jiahao Jiang, Jiang Fan
exaly  

Reassessing the steroid-sparing potential of efgartigimod in gMG

Journal of the Neurological Sciences
Jie, Yuan, Xuemei, Li, Yuan, Liu
openaire   +2 more sources

Efgartigimod is a new option for the treatment of thymoma associated myasthenia gravis: A case report

International Journal of Surgery Case Reports
Lirong Jin, Jianyong Ding
exaly  

Efgartigimod bei CIDP effektiv

Fortschritte der Neurologie · Psychiatrie
openaire   +1 more source

Successful Treatment of Evans Syndrome With efgartigimod: A Case Report

American Journal of Therapeutics
Yasuyuki, Inoue, Shigeki, Kosugi
openaire   +2 more sources

Case report: Rapid symptom relief in autoimmune encephalitis with efgartigimod: a three-patient case series

Frontiers in Immunology
Qi Niu
exaly  

Efgartigimod-alfa/immune-globulin

Reactions Weekly
openaire   +1 more source